[Treatment of clinically localized prostatic cancer--endocrine therapy].
We assessed the actuarial survival of 28 patients with localized prostate cancer who were treated with endocrine therapy in comparison with that of 19 patients who had radical prostatectomy between 1972 and 1995. There were no significant differences among the cause-specific curves and clinical disease-free survival of patients treated with endocrine therapy and radical prostatectomy but the all-cause survival curves favored the surgery group. The results of endocrine therapy alone were unsatisfactory for the patients with high grade tumors. In conclusion, the patients with localized prostate cancer at high risk of death from other complications are reasonable candidates for endocrine therapy.
Hirano
A
A
Department of Urology, Wakayama Medical College.
D000206:Actuarial Analysis; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D000368:Aged; D000369:Aged, 80 and over; D004054:Diethylstilbestrol / Q000627:therapeutic use*; D018572:Disease-Free Survival; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011468:Prostatectomy / Q000401:mortality; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery
D007987:Gonadotropin-Releasing Hormone; D004054:Diethylstilbestrol